title: Why Biologic Therapies Sometimes Lose Efficacy.
abstract: Biologic therapies for psoriasis are associated with loss of response over time. Immunogenicity, suboptimal dosing, low serum drug levels, and intermittent or episodic therapy have been documented as explanations for this phenomenon. Use of an immunomodulatory agent can reduce the risk of immunogenicity and improve clinical response.
authors.affiliation: Professor and Chair Department of Dermatology University of Connecticut Health Center Farmington, Connecticut.
authors.forename: Bruce E
authors.initials: BE
authors.lastname: Strober
mesh_terms: D000068879:Adalimumab / Q000008:administration & dosage* / Q000009:adverse effects; D001688:Biological Products / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D011565:Psoriasis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D001688:Biological Products; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D000068879:Adalimumab
keywords: Anti-drug antibodies; biologics;; immunogenicity;; loss of
  response; psoriasis; serum drug levels